Staff Reports
A short Facebook video by 15‑year‑old Will Roberts changed the course of his care. The Alabama teen, battling aggressive osteosarcoma that stopped responding to standard chemotherapy, posted a plea asking for help. That plea went viral, people in President Donald Trump’s orbit and federal health officials took notice, and reporters say the family was quickly moved to Santa Monica to begin an experimental gene therapy called DeltaRex‑G.
How a viral plea cut through red tape
Will’s video said the chemo wasn’t working and that he was running out of options. Within days, the clip reached donors, private citizens, Former First Lady Melania Trump, Health and Human Services Secretary Robert F. Kennedy Jr., and Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz. Reports say Dr. Oz helped connect the family with the Sarcoma Oncology Center in Santa Monica, telehealth visits were set up, travel was arranged, and the teen reportedly received an initial dose of DeltaRex‑G. A public fundraising drive soared, too — a community pitched in to help cover the huge costs. If true, this was fast action: a private network plus government officials using discretion to get a child access to an experimental treatment when conventional routes had stalled.
What DeltaRex‑G is — and what it isn’t
DeltaRex‑G is an investigational tumor‑targeted gene therapy that has been used in small trials and expanded‑access programs for tough, treatment‑resistant cancers, including sarcomas. It’s not a broadly approved, standard therapy for osteosarcoma. That matters. Parents and doctors are desperate when standard chemo fails, and early reports from small studies have shown occasional responses. But the therapy remains experimental in the U.S., so any use is done under clinical or expanded‑access pathways and carries real risks. Still, when a 15‑year‑old reads the medical room correctly and asks for help, the humane answer is not a stack of denials — it’s to explore every credible path forward.
Politics, compassion, and the right‑to‑try
Call it MAGA medicine or call it common sense: conservatives have long argued for right‑to‑try and expanded access so dying patients can pursue promising, investigational drugs. In this case, President Donald Trump’s team and officials like Secretary Kennedy and Administrator Dr. Mehmet Oz are being credited with cutting through hurdles and helping a family move fast. That should be applauded. The alternative — a slow march through bureaucracy while a child’s clock ticks — is unconscionable. If this story also nudges regulators to make safe, transparent, and faster pathways available for desperate patients, that’s a win for patients of every political stripe.
What this should teach Washington
Will Roberts’ plea should be more than a headline and a fundraiser. It should be a wake‑up call. We need clearer, faster, and safer ways to get investigational treatments to patients who have exhausted standard options, with proper oversight and pediatric safeguards. We also need honest transparency from clinics and agencies about what was done for this family — paperwork, consents, and clinical plans matter. For now, hope rests with a brave boy, caring donors, and officials who moved. If results follow, fine. If not, the lesson still stands: when people ask for help, government should streamline the path to potential cures, not expand obstacles. Will deserves that effort — and so do every other families watching this happen.
